| Project/Area Number |
16590315
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Experimental pathology
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
UENAKA Akiko Okayama University, Graduate School of Medicine, Dentistry and Pharmacology, Lecturer, 大学院・医歯薬学総合研究科, 講師 (50273967)
|
|---|
| Project Period (FY) |
2004 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2005: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2004: ¥2,400,000 (Direct Cost: ¥2,400,000)
|
|---|
| Keywords | tumor / antigen / ELISPOT cloning / IFNγ / monoclonal antibody / NY-ESO-1 / monitoring / 細胞・組織 / 腫瘍抗原 / 細胞傷害性T細胞(CTL) / エリスポトクローニング / 腎癌 / 肺癌 / Meth A / RL male 1 |
|---|
| Research Abstract |
CD8 T cells can recognize MHC and peptide on the cell surface and kill the cells directly. Increasing the effector CD8 T cells recognizing tumor by vaccination of tumor rejection antigen or epitope peptides is an expectation for therapies of cancer. The identification of the tumor rejection antigens and CTL epitope peptides is a main theme for this purpose.
Recently, we improved the new method of T cell antigen cloning with the sensitivity and the efficacy by using large and small-scale ELISPOT assays. In mouse model system, the tumor rejection antigen of Meth A sarcoma, ramp (retinoic acid-regulated nuclear matrix-associated protein) was identified by ELISPOT-cloning by using this new improved method. For identification of human-lung-cell-carcinoma antigen recognized by tumor specific CD8 T cells, the cDNA library was prepared from mRNA of tumor cells and transfected them into 293T cells with HLA gene. And then assayed the transfected 293T cells to stimulate autologous tumor specific CD8 T cells to produce IFNγ. We have finished the first and second screening by large-scale ELISPOT assay.
For analysis of the expression and cellular localization of the tumor antigen, XAGE-1b, defined by SEREX, mAbs for XAGE-1b were produced.
On going phase I study of the CHP-NY-EO-1 vaccination, NY-EO-1 specific CD4-T and CD8-T cell responses were analyzed pre and after vaccination. The increased responses of CD4 T cells were found after the second vaccination by IENγ secretion assay.
|
